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Introduction 
The bioaccumulative potential and toxicity of polychlorinated biphenyls (PCBs) and polybrominated 
diphenylethers (PBDEs) in marine mammals has been the focus of numerous papers worldwide. Although PCBs 
and PBDEs may undergo metabolic/enzymatic breakdown leading to methylsulfone and hydroxylated 
metabolites1, recent concerns have been raised about the presence and health effects of some of these metabolites 
in wildlife. Harbour seals (Phoca vitulina) are common pinnipeds in European coastal waters. They are known to 
accumulate high PCB and PBDE concentrations in their tissues because of their longer life spans and top-
position in aquatic food chains2,3. Profiles of PCB and PBDE congeners in harbour seals suggest that these 
animals have a higher capacity of metabolizing several congeners compared to other marine mammal species4. 
However, considering the assumed toxicity of the resulting metabolites, a higher metabolism of PCBs and 
PBDEs might not be an advantage after all. The objective of the present study was to investigate the levels and 
profiles of PCBs, PBDEs and their hydroxylated metabolites in blood of free-ranging harbour seals in order to 
elucidate the metabolism of PCBs and PBDEs. 
 
Materials & Methods 
Samples, chemicals and target compounds. Blood samples were collected from 31 harbour seals caught in seal-
catch campaigns organised on Helgoland and Lorenzenplate (North Sea, Germany) in 2006 and 2007. Seals were 
physically restrained. Blood was drawn from the extradural venous sinus into sterile evacuated blood collection 
tubes (serum tubes Monovette®, Germany) and kept at -20°C.  Serum was isolated by centrifugation at 1500g 
during 20 min at 20°C (Multifuge 3 S-R, Kendro). In all samples, the following 22 HO-PCB congeners were 
investigated: 3-HO-CBs (numbers 118, 153, 138 and 180), 4-HO-CBs (numbers 120, 107, 146, 127, 130, 163, 
187, 162, 202, 177, 172, 193, 198, 199 and 208), 4,4’-diHO-CB 202. Additionally two unknown HO-tetraCBs 
were also measured. The following 8 HO-PBDEs were also targeted: 2’-HO-BDE 68, 3-HO-BDE 47, 5-HO-
BDE 47, 6-HO-BDE 47, 4-HO-BDE 42, 4’-HO-BDE 49, 6-HO-BDE 99 and 4-HO-BDE 90. Standards were 
from Accustandard (HO-PBDEs) or from Wellington Laboratories (HO-PCBs). 
 
Sample preparation. The method for serum analysis was adapted from the methods described by Covaci and 
Voorspoels5 for the determination of neutral compounds in serum and by Weiss et al.6  for the determination of 
phenolic compounds. A volume of serum (~ 1.5 ml) was spiked with internal standards (PCB 143 and BDE 77 
for neutrals and 4’-HO-CB 159 for phenolics), diluted 1:1 with Milli Q water, mixed with formic acid, sonicated 
for 20 min and extracted using solid-phase extraction (SPE) cartridges (6 ml/500 mg Oasis HLB, Waters). 
Elution was done by 10 ml of MeOH:DCM (1:1, v/v). After evaporation to near dryness, the analytes were 
reconstituted in 500 µl hexane:DCM (1:1, v/v) and fractionated on silica SPE cartridges (3ml/500 mg, Varian). A 
first fraction containing PCBs and PBDEs was eluted with 5 ml hexane, while the phenolic compounds were 
eluted with 6 ml MeOH:DCM (1:1, v/v). Both fractions were evaporated to dryness.  
The first fraction (neutrals) was cleaned-up on 500 mg acid silica (44%, w/w) and the analytes were eluted with 8 
ml hexane:DCM (1:1, v/v). The cleaned extract was evaporated to dryness under a gentle nitrogen stream and 
reconstituted in 100 µl iso-octane. The second fraction (phenolics) was derivatized for 30 min with 
diazomethane when MeO-PCBs and MeO-PBDEs were formed. After solvent evaporation, the dried residue was 
reconstituted in 200 µl DCM and further cleaned-up on 500 mg acid silica (25%, w/w). Methoxylated 
Organohalogen Compounds, Volume 70 (2008) page 000837
2 
 
compounds were eluted with 10 ml hexane:DCM (1:1, v/v), the extract was evaporated to dryness under a gentle 
nitrogen stream and reconstituted in 100 µl iso-octane. 
 
Analysis. For the analysis of methoxylated derivatives and of PBDEs, a GC-MS operated in electron capture 
negative ionisation (ECNI) mode was equipped with a 30 m x 0.25 mm x 0.25 µm DB-5 capillary column (J&W 
Scientific). The ion source temperature was 170 °C. The MS was used in the SIM mode with two ions monitored 
for each MeO-PCB congener in specific windows, while ions m/z = 79 and 81 were monitored for MeO-PBDEs 
and for PBDEs during the entire run. Two µl of the extract were injected in cold pulsed splitless mode, splitless 
time 1.50 min. Helium was used at constant flow (1.0 ml/min). For the PCB analysis, a GC-MS operated in 
electron impact ionisation (EI) mode was equipped with a 25 m x 0.22 mm x 0.25 µm HT-8 capillary column 
(SGE). The ion source temperature was 230 °C. The MS was used in the SIM mode with two ions monitored for 
each PCB homologue group in specific windows. Two µl of the extract were injected in cold pulsed splitless 
mode, splitless time 1.50 min. Helium was used at constant flow (1.0 ml/min). 
 
Quality Assurance/Quality Control (QA/QC). Multi-level calibration curves (r2 > 0.999) in the linear response 
interval of the detector were created for the quantification. QC was performed by regular analyses of procedural 
blanks, by random injection of standards, spiked samples and solvent blanks. The quality control scheme is also 
assessed through regular participation to interlaboratory comparison exercises organized by AMAP (POPs in 
serum). Obtained values were deviating with less than 10% from the consensus values. The mean recovery of 
internal standard 4’-HO-CB 159 in serum was 96 ± 2 %. Recoveries assessed through spiking experiments at 25 
and 125 pg/ml ranged between 90 and 93% with precision (RSD) < 2 %. For analytes detected in the procedural 
blanks, the mean procedural blank value was used for subtraction. After blank subtraction, the limit of 
quantification (LOQ) was set at 3 times the standard deviation of the procedural blank. For analytes that were not 
detected in procedural blanks (all HO-PCBs and HO-PBDEs), LOQs were calculated for S/N=10.  
 
Statistical analysis. Statistical analyses were conducted using SPSS 14.0 Statistical Package. Differences 
between possible groups were detected using one-way ANOVA followed by Tukey’s post hoc test. Outliers were 
found by making boxplots and removed for further calculations (means and standard deviations). The level of 
statistical significance was defined at p < 0.05.  
 
Results and discussion 
At first, samples were divided according to age (between 6 and 18 months or older than 18 months) and gender 
(male or female), resulting in 4 groups. However, for each congener and metabolite, no statistical significant 
differences were found between groups (all p > 0.05; one-way ANOVA followed by Tukey’s post hoc test). 
Therefore all samples were pooled. 
 
Levels and profiles of PCBs and PBDEs. Congener BDE 28 was not detected in any investigated sample, while 
congeners CB 110, BDE 99 and BDE 153 were found in less than 50 % of all samples. Values of sum PCBs 
were more than 200 times higher compared to concentrations of sum PBDEs, with values ranging from 10573 
pg/ml to 193822 pg/ml for sum PCBs and 22 pg/ml to 648 pg/ml for sum PBDEs. For PCBs, CB 153 was the 
most dominant or persistent congener in all samples, followed by respectively CB 138, CB 187 and CB 180 (Fig. 
1A). This profile was previously also found in blood samples7 and blubber samples4 of harbour seals and is well 
conserved in this species8-10. For PBDEs, BDE 47 and BDE 100 were the most dominant congeners. Other 
congeners, such as BDE 99, BDE 153 and BDE 154 (Fig. 1B), were of reduced importance resulting in a 
different profile compared to that found in blubber3,4. 
 
Levels and profiles of PCB and PBDE metabolites. Although the behavior of HO-PBDEs is assumed to be 
similar compared to HO-PCBs11 and biotransformation of PBDEs in beluga whales was earlier shown to occur12, 
no HO-PBDEs were found in the investigated blood samples. This is a confirmation of the results of a recent 
study13, performed in blood of pregnant women and their infants in the Netherlands, which was also unable to 
detect a HO-PBDE (6-HO-BDE 47). However, very low, yet measurable HO-PBDE concentrations were 
detected in beluga whale livers14. Some HO-PCBs (3-HO-CB 118 and 4-HO-CB 127) were not found in any 
sample, while 4-HO-CB 199, 3-HO-CB 180 and 4,4’-diHO-CB 202 were detected in less than 50 % of all 
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samples. In the present study, the highest concentration was found for the lowest chlorinated compound (4-HO-














































































































Fig. 1. Mean concentrations of precursor PCBs (A) and PBDEs (B) in serum of harbour seals. Error bars 




































































































































Fig. 2. Mean concentrations of HO-PCBs in serum of harbour seals. Error bars represent standard deviation.  
 
Relationships between metabolites and precursor compounds. In general, levels of sum PCBs were 10 times 
higher than levels of their metabolites (ratio ΣHO-PCBs/ΣPCBs = 0.103). Ratios smaller than 1 were also found 
for bottlenose dolphins (Tursiops truncatus) from the Indian River Lagoon (Florida, USA) and Charleston15, for 
ringed seals from Québec, Canada (Phoca hispida)16 and for bowhead whales (Balaena mysticetus) from 
Alaska17. In contrary, ratios greater than 1 were detected in polar bears (Ursus maritimus) from Canada16 and 
Greenland18. Formation of PCB metabolites may occur via direct insertion and/or NIH shift1. In this study, a 
good correlation (R2 = 0.81) was found between the sum of HO-PCBs and their possible precursor congeners 
(Fig. 3), suggesting a metabolism of precursor PCBs independent of the body burden. However, unknown 
amounts of HO-PCBs might also be ingested directly through food or transferred from mother to offspring13.   
 
Comparison with harbour porpoise. In addition to the 31 harbour seals, serum of an adult male harbour 
porpoise (stranded at the Belgian coast in 2003) was included in the analysis as well. This animal had a 
concentration of sum HO-PCBs of 202 pg/ml, which was more than 25 times lower compared to the harbour 
seals and a concentration of sum PCBs of 800 ng/ml which was almost 5 times higher than the harbour seals. 
Although it is impossible to draw firm conclusions, this suggests that metabolization of PCBs in harbour 
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Fig. 3. Relationship between hydroxylated PCB-metabolites and their possible precursor congeners as stated in 
the table. Only congeners in bold were measured in present study and were therefore included in the calculations. 
Possible precursors were taken from Jaspers et al19. (*) double insertion. 
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HO-compounds PCB precursors 
direct insertion NIH-shift 
4-HO-CB107 CB 107  CB 118, 105 
3-HO-CB118 CB 118 ? 
4-HO-CB120 CB 120 CB 118 
4-HO-CB130 CB 130 CB 128, 138 
3-HO-CB138 CB 138 CB 130, 157 
4-HO-CB146 CB 146 CB 138, 153 
3-HO-CB153 CB 153 CB 146, 128 
4-HO-CB172 CB 172 CB 170, 180 
3-HO-CB180 CB 180 CB 172 
4-HO-CB187 CB 187 CB 183 
4-HO-CB-199 CB 199 CB 204 
4-HO-CB202 CB 202 CB 199 
4,4’-diHO-CB202 CB 202 (*) CB 199 
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